Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
SIGNIFOR LAR pasireotide 20 mg (as embonate) modified release powder for injection vial and 2 mL diluent in prefilled syringe composite pack, Accelagen (agent on behalf of the sponsor, Recordati Rare Diseases Australia), CON-419
Product name
SIGNIFOR LAR pasireotide 20 mg (as embonate) modified release powder for injection vial and 2 mL diluent in prefilled syringe composite pack
Sponsor name
Accelagen (agent on behalf of the sponsor, Recordati Rare Diseases Australia)
Consent start
Consent no.
CON-419
Standard
Paragraph 8(1)(i) and 10(5)(g) in the Therapeutic Goods Order No. 91 - Standard for labels of prescription and related medicines
Non-compliance with standard
The productslabels state the sponsor is Novartis, which does not reflect the
current sponsorship of the product as Recordati Rare Diseases Australia Pty
Ltdpre-filled syringe diluent label of SIGNIFOR LAR does not include the
approved route of administration of the medicine
Therapeutic product type
Prescription medicines